Opportunity ID: 328858
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | PAR-20-295 |
Funding Opportunity Title: | Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Aug 28, 2020 |
Last Updated Date: | Sep 23, 2020 |
Original Closing Date for Applications: | Oct 13, 2021 |
Current Closing Date for Applications: | Oct 13, 2021 |
Archive Date: | Nov 18, 2021 |
Estimated Total Program Funding: | – |
Award Ceiling: | $500,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Native American tribal governments (Federally recognized) State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education Special district governments Public housing authorities/Indian housing authorities County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: |
[The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies |
Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-295.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Updated eligibility in accordance with NOT-CA-20-107 | Sep 23, 2020 | |
Aug 28, 2020 |
DISPLAYING: Synopsis 2
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | PAR-20-295 |
Funding Opportunity Title: | Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Aug 28, 2020 |
Last Updated Date: | Sep 23, 2020 |
Original Closing Date for Applications: | Oct 13, 2021 |
Current Closing Date for Applications: | Oct 13, 2021 |
Archive Date: | Nov 18, 2021 |
Estimated Total Program Funding: | – |
Award Ceiling: | $500,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Native American tribal governments (Federally recognized) State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education Special district governments Public housing authorities/Indian housing authorities County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: |
[The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies |
Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-295.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | PAR-20-295 |
Funding Opportunity Title: | Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Aug 28, 2020 |
Last Updated Date: | Aug 28, 2020 |
Original Closing Date for Applications: | – |
Current Closing Date for Applications: | Oct 13, 2021 |
Archive Date: | Nov 18, 2021 |
Estimated Total Program Funding: | – |
Award Ceiling: | $500,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Small businesses City or township governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities State governments County governments Independent school districts For profit organizations other than small businesses |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | [The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies |
Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-295.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
Packages
Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-F | Use for due dates on or before January 24, 2022 | PKG00263172 | Jan 10, 2021 | Jan 24, 2022 | View |